Galectin Therapeutics Inc

GALT

Company Profile

  • Business description

    Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

  • Contact

    4960 Peachtree Industrial Boulevard
    Suite 240
    NorcrossGA30071
    USA

    T: +1 678 620-3186

    E: [email protected]

    https://www.galectintherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,758.66300.360.68%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,641.2929.950.15%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,287.7124.450.39%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers